[ node.tpl : 'full']
Obese breast cancer patients have higher levels of oestrogen even on hormone suppressants, which suggests they might benefit from altered treatment.
The study, led by a team at The Institute of Cancer Research in London and the Royal Marsden NHS Foundation Trust, found hormone-suppressing drugs did markedly reduce oestrogen levels in obese women – but that their levels of oestrogen remained more than double those of women of normal weight.
The research, which is published today in the Journal of Clinical Oncology, could lead to improvements in doctors’ ability to select the most appropriate treatment for overweight and obese women. But scientists stressed the effect of obesity was modest and that women being treated for breast cancer should not be concerned by the findings.
Over three-quarters of breast cancers require oestrogen to grow, so one of the main ways of treating the disease is by blocking the hormone’s production or action. Obese women have higher levels of oestrogen than women of normal weight, and the new findings show that although their oestrogen levels are markedly reduced with hormone-suppressing drugs called aromatase inhibitors, the levels are higher during treatment than those in similarly treated normal weight women.
Senior author Professor Mitch Dowsett, a team leader in the Breakthrough Breast Cancer Research Centre at The Institute of Cancer Research and head of the academic department of biochemistry at The Royal Marsden, said:
“We found that women with higher BMIs had more oestrogen remaining in their blood after treatment than healthy-weight women, which is consistent with previous suggestions that aromatase inhibitors might be slightly less effective in these women.
“Our findings are based on laboratory studies, so we would need to carry out clinical trials to tell us whether women with a higher BMI would benefit from changes to their treatment. Women with higher BMIs should certainly not be alarmed by this finding or stop taking their treatment. Our study takes us a step closer to understanding which of the treatment options available might be the most suitable for individual women.”
Professor Dowsett and colleagues set out to probe a recent study that indicated the aromatase inhibitor anastrozole was no more effective than older-style tamoxifen in women with higher BMI, unlike in the general population where it is clearly more effective.
One possible explanation is that tamoxifen is more effective in overweight women, but the team wanted to investigate the other possibility – that in these women aromatase inhibitors are less effective.
The scientists examined two aromatase inhibitors: anastrozole and a more potent drug called letrozole. Their study included 54 postmenopausal women with oestrogen receptor positive breast cancer, given either three months of adjuvant anastrozole followed by three months of letrozole, or the drugs in the opposite sequence. Data on body mass index (BMI) and oestrogen levels – before and after treatment with the first drug, as measured by levels of estradiol and oestrone sulphate in the blood - were available for 44 patients.
The study found that, prior to treatment, women with higher BMIs had higher oestrogen levels – those with BMIs from 30 to 35 had around three times more plasma oestrogen than those with BMIs of less than 25.
After treatment with letrozole, women with BMIs of 30 to 35 still had levels of plasma oestrogen nearly three times as high as for healthy-weight women. The same trend was found for anastrozole, but did not reach statistical significance.
Dr Julia Wilson, Head of Research at Breakthrough Breast Cancer, said: “This study shows that size does matter when it comes to breast cancer treatment. We can improve survival for obese women if we know which drugs are more likely to work for them, and avoid those which are less likely to succeed. We want each breast cancer patient to get the right treatment for their specific needs and this is a step in that direction.”
The study received funding from Breakthrough Breast Cancer and through the National Institute for Health Research’s Biomedical Research Centre for Cancer at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.